Develops experimental medicines for patients with immune-mediated diseases, including dry eye disease, allergic conjunctivitis, and retinal conditions.
10-K for FY2025, filed Feb 27, 2026Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our…View ↗
No revenue reported yet.
10-K for FY2025, filed Feb 27, 2026
Aldeyra expects to commercialize approved products itself or through pharmaceutical partners. AbbVie has an option for a U.S. collaboration and an exclusive license outside the U.S. for reproxalap.
10-K for FY2025, filed Feb 27, 2026We have no products approved for sale in the United States or elsewhere. We will not receive any revenue from sales of our product…View ↗
We have retained worldwide commercial rights for our product candidates, provided, however, that on October 31, 2023, we entered into the…View ↗
On October 31, 2023 (the AbbVie Option Agreement Effective Date), we entered into an exclusive option agreement (the AbbVie Option…View ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
−$3.8MView ↗
8-K, filed Nov 9, 2026
On November 9, 2026, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) announced that the Company has formally requested that the…View ↗
8-K, filed Sep 29, 2026
On September 25, 2026, Aldeyra Therapeutics, Inc. (Aldeyra) held a Type D meeting with the U.S. Food and Drug Administration (FDA)…View ↗
RASP pipeline focus
The older report highlighted an oral RASP candidate for systemic conditions. The latest describes RASP candidates for systemic and retinal diseases and identifies late-stage candidates for dry eye disease, allergic conjunctivitis, and retinal conditions.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Feb 27, 2026We are a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. We are developing a…View ↗
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our…View ↗
Competes with AbbVie, Johnson & Johnson, UCB, Amgen, Bristol-Myers Squibb, Eli Lilly, Novartis, Regeneron Pharmaceuticals, Roche, Sanofi, Takeda, AstraZeneca, GlaxoSmithKline, Merck, and Pfizer
10-K for FY2025, filed Feb 27, 2026A myriad of new treatments have been or are being developed to treat inflammatory diseases, and have been used, or in theory could be used…View ↗
Loading...